Rate My Professor Johannes Yeh

Johannes Yeh is a Research Associate Professor and Director of the CSHL Antibody and Phage Display Shared Resource at Cold Spring Harbor Laboratory, where he also serves as a Cancer Center Member. He earned his Ph.D. from the University of Cambridge in 2006 and holds a DDS PhD. Before joining CSHL, Yeh was a Postdoctoral Fellow in the laboratory of Norbert Perrimon at Harvard Medical School from 2009 to 2013 and subsequently worked as a Research Scientist at Serono. At CSHL, he leads the Yeh Lab, which employs biomolecular engineering approaches to investigate dysregulated cell signaling mechanisms underlying diseases such as cancer. The lab dissects signal transduction pathways and develops therapeutics, including inhibitors targeting oncogenic receptors, transcription factors, and extracellular matrix proteins, as well as biologics to modulate interactions between cancer cells and the tumor microenvironment.

The Yeh Lab's research has produced impactful publications, including 'Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice' in Science (2018), 'Manipulating PTPRD function with ectodomain antibodies' in Genes & Development (2023), 'Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies to self-antigens' in JCI Insight (2023), 'A synthetic KLHL20 ligand to validate CUL3KLHL20 as a potent E3 ligase for targeted protein degradation' in Genes & Development (2022), and 'Temporal and Spatial Characterization of CUL3KLHL20-Driven Targeted Degradation of BET Family BRD Proteins by the Macrocycle-Based Degrader BTR2004' in ACS Chemical Biology (2025). Yeh directs the Antibody and Phage Display Shared Resource, providing custom antibodies and phage display services to support cancer research at CSHL. His work advances understanding of cancer pathophysiology and therapeutic development through engineering-based strategies.